Mitomycin Accord

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic presented as a sterile solution for intravenous and intravesical use. It is employed in the treatment of several solid tumours, including bladder cancer when administered directly into the bladder, and systemic cancers such as gastric, pancreatic, breast and non‑small cell lung cancer.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Accord is used in oncology to target malignant cells across several tumour types.

- Bladder cancer (intravesical): provides local cytotoxic therapy to reduce tumour recurrence. - Gastric cancer: contributes to tumour shrinkage as part of combination chemotherapy. - Pancreatic cancer: used in systemic regimens to improve response rates. - Breast cancer: incorporated into multi‑agent protocols for advanced disease. - Non‑small cell lung cancer: added to chemotherapy schedules to enhance efficacy.

Adverse reactions to Mitomycin Accord vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Myelosuppression (decreased blood cell counts) - Alopecia (hair loss) - Fatigue - Mucositis (inflammation of mucous membranes) - Diarrhoea

Serious or Rare Side Effects: - Bone marrow failure - Severe infection (sepsis) - Pulmonary toxicity (interstitial pneumonitis) - Hemolytic‑uremic syndrome - Renal toxicity - Anaphylactic or severe allergic reactions

Mitomycin Accord requires careful clinical monitoring before and during therapy.

- Renal function: assess baseline creatinine and monitor during treatment. - Hematologic status: perform regular complete blood counts to detect myelosuppression. - Pregnancy: avoid use unless potential benefit justifies the risk. - Concurrent radiation therapy: use with caution due to additive tissue toxicity. - Drug interactions: review concomitant medications for additive myelosuppressive or nephrotoxic effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin Accord may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: increased cumulative toxicity. - Strong CYP450 inducers (e.g., rifampicin): may reduce plasma concentrations. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides): monitor renal function closely. - Myelosuppressive agents (e.g., methotrexate): watch blood counts for additive suppression. - Antifungal azoles (e.g., fluconazole): may increase Mitomycin exposure, adjust monitoring.